NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects.
This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in combination with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any investigational treatment(s) or marketed product(s), intended to be administered to a study patient according to the study enrollment.
Part 1 will enroll relapsed/refractory MM and NHL patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a chimeric antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who previously received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone and/or in combination with daratumumab, and Cohort C will enroll iNHL patients who previously received rituximab and other therapies to receive NKTR-255 alone and/or in combination with rituximab.
SparkCures ID | 1045 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 118 Patients |
Treatments | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
Key Inclusion Criteria:
Patient has the following laboratory test results during Screening:
Patients are eligible who also meet all the following criteria in these cohorts of Part 2:
Cohort A only:
• Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD.
Cohort B only:
Cohort C only:
• Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
The following criteria is provided for health care professionals.
Key Inclusion Criteria:
Patient has the following laboratory test results during Screening:
Patients are eligible who also meet all the following criteria in these cohorts of Part 2:
Cohort A only:
• Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD.
Cohort B only:
Cohort C only:
• Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
The following is a listing of trial locations that are open and accepting patients.
SparkCures Verified Accurate, up-to-date information. Learn more
Goodyear, AZ
Tampa, FL
Ann Arbor, MI
Minneapolis, MN
Valhalla, NY
Fairfax, VA
The following is a listing of trial locations that are not currently open and accepting patients.
Goodyear, AZ
SparkCures Verified Accurate, up-to-date information. Learn more
Tampa, FL
Ann Arbor, MI
Minneapolis, MN
SparkCures Verified Accurate, up-to-date information. Learn more
Valhalla, NY
Fairfax, VA
There are no resources, links or videos to display for this clinical trial.
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message